The International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies has gained a reputation over the past 18 years as the premier meeting on antiviral resistance.  Leading laboratory and clinical scientists present their latest research at this Workshop, which often results in innovative approaches to antiviral therapy.  The Workshop is renowned for the quality of the data presented and the depth of the scientific interaction and debate.
This year the workshop is being held at the Hotel Croatia in Dubrovnik, Croatia on June 8-12, 2010.

The Workshop continues to attract the most prominent scientists and clinicians, thereby maintaining the Workshop's excellent reputation for cutting-edge science and service. Additionally, through support of our Funding Partners, scholarships are available for young scientists and community representatives.

HBV/HCV Resistance
In view of the rapidly expanding area of HBV/HCV drug development and the many parallels with antiretroviral therapy, the Scientific Committee is building on last year’s success with the addition of HBV/HCV resistance content.

HIV Drug Resistance in Resource Poor Countries
One of the topics that will be highlighted at this year’s Resistance Workshop is the emergence of HIV drug resistance as a consequence of the global expansion antiretroviral therapy. In past six years, the number of people receiving antiretroviral therapy in low and middle-income countries has increased ten-fold, reaching almost 3 million people by the end of 2007. This enormous progress is potentially threatened by the selection and transmission of HIV drug resistance. It is important that all scientists investigating HIV drug resistance internationally share data and ideas, as well as develop potential synergistic collaborations.

Investigators working on HIV-1 drug resistance in developing countries are strongly encouraged to submit abstracts describing their latest findings to the Workshop.

HIV-1 Persistence, Reservoirs and Elimination Strategies
Current antiretroviral therapy suppresses HIV-1 infection but cannot eradicate it because there are long-lived cellular reservoirs that are latently infected or that chronically produce HIV-1. These reservoirs are likely to be the source of residual low-level viremia on antiretroviral therapy, although ongoing, complete cycles of HIV-1 replication have not been excluded. The persistence of HIV-1 requires new insights into the molecular basis of latency, the cellular and anatomic reservoirs of HIV-1, the immunopathogenic consequence of viral persistence, and novel approaches to reduce or eliminate viral expression and cellular reservoirs.

Investigators working on HIV-1 persistence, reservoirs and elimination strategies are strongly encouraged to submit abstracts describing their latest findings to the Workshop.